DALLAS, April 9, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Labopharm Inc. (Nasdaq:DDSS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/DDSS
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Labopharm Inc. (DDSS) is an international specialty pharmaceutical company focused on improving existing drugs by incorporating its advanced controlled-release technologies. The Company develops products internally in order to enter into strategic alliances or licensing agreements with national or international pharmaceutical companies that have the necessary resources and distribution networks to market and sell its pharmaceutical products. The Company's wholly owned subsidiaries include Labopharm Europe Ltd., Labopharm (Barbados) Ltd., Labopharm Cyprus Ltd.and Labopharm USA Inc.
Message Board Search for DDSS: http://www.boardcentral.com/boards/DDSS
In the report, the analyst notes:
"Revenue from product sales in all territories for the fourth quarter of fiscal 2009 increased to $4.7 million from $3.3 million for the fourth quarter of fiscal 2008. Revenue from product sales to territories other than the United States was $4.5 million compared with $3.3 million for the fourth quarter of fiscal 2008. The increase was the result of both higher sales volumes and a higher average selling price in the fourth quarter of 2009. Total revenue for the fourth quarter of fiscal 2009 was $6.7 million compared with $4.4 million for the fourth quarter of fiscal 2008.
"DDSS recently announced its wholly owned subsidiary, Labopharm Europe Ltd., has completed a licensing and distribution agreement for once-daily tramadol with Nippon Shinyaku Co. Ltd. of Japan. DDSS will receive an up-front payment upon signature of the agreement and is eligible to receive additional payments related to the achievement of certain regulatory and commercialization milestones. Under the terms of the agreement, Nippon Shinyaku has the exclusive right to market and sell DDSS's once-daily tramadol product in Japan."
To read the entire report visit: http://www.stockpreacher.com/n/DDSS
See what investors are saying about DDSS at penny stock forum
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. StockPreacher.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.